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Abstract
Purpose: Methylation-induced silencing of PRSS3 has been shown to be significantly associated with invasive bladder
cancer, and expression of the C16orf74 gene locus has been shown to correlate positively with PRSS3. The aim of the current
study was to evaluate the relationship between C16orf74 expression level and progression in non-muscle invasive bladder
cancer (NMIBC).
Materials and Methods: C16orf74 mRNA levels were examined by real-time reverse transcriptase polymerase chain reaction
(RT-PCR) analysis of 193 tumor specimens from patients with primary NMIBC. Expression data were analyzed in terms of
clinical and experimental parameters. Kaplan-Meier curves and multivariate Cox regression models, respectively, were used
to determine progression-free survival and to identify independent predictive parameters of progression.
Results: Analysis using Kaplan-Meier curves revealed prolonged progression-free survival of high-C16orf74-expressors as
compared to low-expressors (p,0.001). Multivariate Cox regression analysis revealed that low C16orf74 mRNA expression
levels are a significant risk factor for disease progression in patients with primary NMIBC (HR: 10.042, CI:2.699–37.360,
p=0.001).
Conclusions: Decreased expression of C16orf74 correlates significantly with progression in primary NMIBC. C16orf74
expression level represents a potentially useful marker for predicting progression in primary NMIBC patients.
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Introduction
More than 90% of bladder cancers are transitional cell
carcinomas, and most are papillary, well-, or moderately-differen-
tiated non-muscle invasive bladder cancer (NMIBC) [1–2]. After
endoscopic resection, cancer recurrence occurs in the majority (50–
70%) of patients with NMIBC [3]. Approximately 20% of these
patients subsequently experience disease progression to muscle
invasive bladder cancer (MIBC) after appropriate treatment,
including transurethral resection (TUR) and intravesical therapy
with epirubicin, mitomycin-C, or Bacillus Calmette-Guerin (BCG)
[1–2]. Thus, frequent recurrence after TUR and subsequent cancer
progression are problematic for patients and urologists alike. Almost
25% of newly diagnosed bladder cancer patients have MIBC, and
the vast majority of these cases are of high histological grade. Nearly
50% of patients with MIBC already have occult distant metastases
at the time of diagnosis [1–2].
A number of potential tumor markers have been identified for
bladder cancer, but few have demonstrated efficacy in terms of
predicting disease recurrence and progression. However, several
recent studies have suggested that the suppressor genes p53,
RUNX3, RASSF1A, and PRSS3 are closely associated with the
development and progression of bladder cancer [4–7]. Specifically,
RASSF1A and PRSS3 promoter methylation is associated with
advanced tumor stage [7], which suggests that these genes might
be associated with bladder cancer progression. PRSS3 in turn has
been shown to be positively associated with C16orf74 expression
[8].
The C16orf74 (MGC17624) gene locus is on chromosome
16q24.1, and its function has yet to be characterized. The results
of several genome-wide studies have indicated that C16orf74 is
involved in inflammatory processes. Tumor necrosis factor (TNF)-
a is a key regulator of the inflammatory cascade in chronic
inflammatory diseases, and in patients with inflammatory disease,
C16orf74 is strongly associated with an anti-TNF response [9].
C16orf74 is a hypoxia regulated gene [10–11]. Winter et al. [10]
reported that C16orf74 median RNA expression level is an
independent prognostic factor for recurrence-free survival in head
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in lymph node-positive metastases in patients with oral tongue
squamous cell carcinoma [12], and to correlate positively with
PRSS3 expression in breast cancer [8].
Recently, we reported the identification of a progression-related
gene classifier that had strong predictive value in terms of disease
outcomes in NMIBC [13]. In that study, C16orf74 was one of eight
candidate genes identified for predicting disease progression in
NMIBC, suggesting a potential relationship between bladder
cancer and C16orf74. In the current study, we assessed the
relationship between C16orf74 and NMIBC outcomes using data




The mean age of the 193 subjects with primary NMIBC was
64.1614.0 years, and the median follow-up period was 44.9
months. Seventy-one patients (36.8%) experienced recurrence and
20 (10.4%) experienced progression. Other baseline characteristics
of the patients are presented in Table 1.
2. The value of C16orf74 mRNA expression level as a
prognostic marker for progression
The relationship between C16orf74 mRNA expression level and
time to progression was analyzed. Using a ROC curve, a cutoff
value (11.7784) for progression with the highest combined
sensitivity (53.2%) and specificity (85%) was determined. Time
to progression was significantly different between the high and low
C16orf74 mRNA expression groups, in that time to progression in
the high C16orf74 expression group was significantly longer than
the low expression group (p,0.001) (Fig. 1). In univariate Cox
regression analysis of several clinicopathological variables (age,
sex, tumor size, number, grade, stage, intravesical therapy, and
C16orf74 mRNA expression levels), age, intravesical therapy and
C16orf74 mRNA expression levels were significant risk factors for
progression (p=0.031, p=0.034 and p,0.001, respectively). In
multivariate Cox regression analysis, age and low C16orf74 mRNA
expression levels were significant risk factors for progression-free
survival in patients with primary NMIBC (HR: 1.049, CI: 1.005–
1.094, p=0.030; and HR: 10.042, CI: 2.699–37.360, p=0.001,
respectively) (Table 2). In multivariate Cox regression analysis in
patients with intravesical therapy, age and low C16orf74 mRNA
expression levels were significant risk factors for progression-free
survival in patients with primary NMIBC with intravesical therapy
(HR1.055, CI: 1.005–1.108, p=0.031; and HR: 14.170, CI:
2.719–73.837, p=0.002, respectively).
Discussion
Trypsin is a member of the serine protease family encoded by
three trypsinogen genes including PRSS1, PRSS2 and PRSS3
encode trypsinogen I, trypsionogen II, and trypsinogen IV (also
known as mesotrypsinogen), respectively [14–16]. This enzyme
has been known as a potent proteolytic enzyme that can destroy
tissue [17–18]. There are conflicting reports in the literature of the
role of trypsin or PRSS3 in tumor progression, with some studies
Table 1. Baseline characteristics of primary non-muscle
invasive bladder cancer patients.
Variables Incidence or mean value (%)
Age (years) 64.1614.0
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Figure 1. Time to progression in non-muscle invasive bladder
cancer according to C16orf74 mRNA expression levels.
doi:10.1371/journal.pone.0015260.g001
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trypsin or PRSS3 plays a tumor suppressive role. The expression
of PRSS3 is reduced in bladder, esophageal, and gastric cancers,
and loss of PRSS3 expression is due to epigenetic silencing
through promoter hypermethylation [7,24–25]. In particular,
silencing of PRSS3 by promoter methylation has been significantly
associated with invasive tumor stage in bladder cancer [7].
The expression of C16orf74 has been shown to correlate
positively with PRSS3. Hockla et al. [8] reported that C16orf74 is
down regulated by knockdown of PRSS3 and upregulated by
mesotrypsin treatment. To date, there have been no reports of an
association of C16orf74 with bladder cancer, except as indicated in
an earlier work by the authors [13]. Here, we analyzed the
relationship between mRNA expression levels of C16orf74 and
progression in primary NMIBC. Reduced expression of C16orf74
was significantly associated with disease progression in NMIBC
patients, suggesting that C16orf74 has a tumor suppressive role,
similar to p53, RUNX3 and PRSS3, in disease progression. To date,
the function of C16orf74 is unknown, and additional studies are
needed to define the precise pathway by which C16orf74 influences
progression in primary NMIBC.
Generally, clinical and pathological parameters such as tumor
grade, tumor stage, lymphatic invasion, tumor size, CIS, papillary
or solid tumor architecture, and multifocality have been
considered useful prognostic parameters for disease progression
in NMIBC. Of these factors, generally tumor grade, stage, and
presence of CIS are considered the most important. In the current
study, intravesical therapy was a risk factor for progression upon
univariate analysis. However, it is possible that patients who
received intravesical therapy were in a clinically high risk group for
recurrence or progression, rather than that the treatment affected
progression [26]. Various molecular markers have also been
evaluated for disease progression. Recently, several studies have
identified putative progression-related genes in NMIBC using gene
expression analysis [27–29]. Wang et al. [27] proposed a 57-gene
panel to help predict progression in NMIBC. Birkhahn et al. [28]
reported that HRAS, VEGFR3, and VEGF expression levels were
related to progression with 81% sensitivity and 94% specificity.
Eguchi et al. [29] reported that the loss of 8p23.3 is a marker for
predicting progression and recurrence in NMIBC. Previously, we
identified a candidate progression-related gene classifier that had
strong predictive value in terms of disease outcomes in NMIBC
[13]. Although C16orf74 is a single molecular marker within this
candidate progression-related gene classifier, it was sufficient to
predict the risk of progression in NMIBC with a strong hazard
ratio of more than 10 upon multivariate analysis.
In the current study, we investigated the mRNA expression
levels of C16orf74 in human primary NMIBC tissues in a relatively
large population with a long-term follow up period, along with
several known clinical risk factors, including age, tumor size,
number of tumors, T-category, tumor grade, and intravesical
therapy [30–31]. These aspects of the study design lend strength to
the results, and strongly suggest that C16orf74 may be a clinically
useful predictor of progression in primary NMIBC.
In conclusion, decreased expression of C16orf74 was significant-
ly associated with progression in primary NMIBC, and the
expression level of C16orf74 was an independent prognostic
determinant for tumor progression. C16orf74 might play a key
role in the progression of NMIBC. Thus, C16orf74 expression level




The Ethics Committee of Chungbuk National University
approved this protocol, and written informed consent was
obtained from each subject. Collection and analysis of all samples
was approved by the Institutional Review Board of Chungbuk
National University.
2. Patients and Tissue Samples
Primary NMIBC samples from patients with histologically-
verified transitional cell carcinoma obtained at our institute were
used for the current study. Patients with concomitant carcinoma in
situ (CIS) or a short term follow-up period (less than 6 months), and
those that underwent radical cystectomy or for whom there was
incomplete data collection, were excluded to make the study
population more homogeneous. A total of 193 primary NMIBC
samples were analyzed.
Table 2. Multivariate Cox regression analysis for prediction of progression in NMIBC and in NMIBC with intravesical therapy.
Variables Total Patients (N=193) Intravesical Tx. Pt. (N=113)
Univariate Cox regression Multivariate Cox regression Multivariate Cox regression
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age (years) 1.043 (1.004–1.083) 0.031 1.049 (1.005–1.094) 0.030 1.055 (1.005–1.108) 0.031
Sex (male vs. female) 0.627 (0.145–2.706) 0.531 0.398 (0.078–2.035) 0.268 0.780 (0.140–4.352) 0.777
Size (,3 cm vs. $3 cm) 1.912 (0.781–4.680) 0.156 2.222 (0.808–6.109) 0.122 1.801 (0.560–5.793) 0.324
Number (Single vs. multiple) 1.885 (0.779–4.562) 0.160 1.391 (0.522–3.706) 0.509 1.424 (0.456–4.452) 0.543
Grade 2.076 (0.989–4.360) 0.054 0.586
G 1 1- 1 - 1-
G2 2.143 (0.698–6.574) 0.183 0.601 (0.130–2.785) 0.515 0.337 (0.042–2.683) 0.304
G3 4.279 (0.942–19.428) 0.060 0.735 (0.090–5.998) 0.774 0.317 (0.024–4.269) 0.386
Stage (Ta vs. T1) 1.294 (0.470–3.565) 0.618 0.608 (0.168–2.195) 0.447 0.865 (0.145–5.151) 0.874
Intravesical Tx. (No vs. Yes) 3.765 (1.102–12.863) 0.034 2.840 (0.666–12.109) 0.158 - -
C16orf74 (high vs. low) 8.940 (2.614–30.576) ,0.001 10.042 (2.699–37.360) 0.001 14.170 (2.719–73.837) 0.002
Tx.: Therapy, Pt.: patients, HR: hazards ratio, CI: confidence interval.
doi:10.1371/journal.pone.0015260.t002
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surgical resection. Each bladder cancer specimen was confirmed
by pathological analysis of a part of the tissue sample in fresh
frozen sections from TUR specimens, and was then frozen in
liquid nitrogen and stored at 280uC until use. A second TUR was
performed 2–4 weeks after the initial resection when a bladder
cancer specimen did not include proper muscle or when high-
grade tumor was detected [32]. Patients who had a T1 tumor,
multiple tumors, large tumors ($3 cm in diameter), or high grade
Ta NMIBC received one cycle of intravesical treatment (BCG or
mitomycin-C) [26,32]. If a patient refused intravesical therapy, it
was not administered after TUR. Response to treatment was
assessed by cystoscopy and urinary cytology. Patients who were
free of disease within 3 months after treatment were assessed every
3 months for the first 2 years and then every 6 months thereafter
[26,32]. Tumors were staged and graded according to the 2002
TNM classification and the 1973 WHO grading system,
respectively [32–33]. Recurrence was defined as recurrence of
primary NMIBC with a lower or the same pathological stage, and
progression was defined as disease with a higher TNM stage upon
relapse.
3. RNA extraction and construction of cDNA
RNA was isolated from tissue using 1 ml of TRIzol (Invitrogen,
Carlsbad, CA) and homogenization in a 5-ml glass tube. The
homogenate was transferred to a 1.5-ml tube and then mixed with
200 ml of chloroform. After incubation for 5 min at 4uC, the
homogenate was centrifuged for 13 minutes (min) at 13,0006g at
4uC. The upper aqueous phase was transferred to a clean tube and
then 500 ml of isopropanol were added. The mixture was
incubated for 60 min at 4uC, and then the tube was subjected to
centrifugation for 8 min at 13,0006g,4 uC. The upper aqueous
phase was discarded and mixed with 500 ml of 75% ethanol, and
then centrifuged for 5 min at 13,0006g,4 uC. After discarding the
upper aqueous layer, the pellet was dried at room temperature,
dissolved in diethylpyrocarbonate (DEPC)-treated water, and then
stored at 280uC. The quality and integrity of the RNA were
confirmed by agarose gel electrophoresis and ethidium bromide
staining, followed by visual inspection under ultraviolet light.
cDNA was prepared from 1 mg of total RNA using a First-Strand
cDNA Synthesis Kit (Amersham Biosciences Europe GmbH,
Freiburg, Germany) according to the manufacturer’s protocol.
4. Real-time PCR
Real-time PCR amplification was performed using a Rotor
Gene 6000 instrument (Corbett Research, Mortlake, Australia) to
quantify the expression of C16orf74. Real-time PCR assays were
carried out in micro-reaction tubes (Corbett Research, Mortlake,
Australia) using SYBR Premix EX Taq (TAKARA BIO INC.,
Otsu, Japan). The primers used for amplification were C16orf74
(179 basepairs) sense (59-AAT GTG TGT CAG CAG CAG CA-
39) and anti-sense (59-TTT CTC CAT CAT CTG GGC AC-39).
The PCR reaction was performed in a final volume of 10 ml
consisting of 5 ml of 2 X SYBR premix EX Taq buffer, 0.5 ml each
of 59- and 39- primer (10 pmol/ml), and 1 ml of the sample cDNA.
The product was purified with a QIAquick Extraction kit
(QIAGEN, Hilden, Germany), quantified with a spectrophotom-
eter (Perkin Elmer MBA2000, Fremont, CA), and then sequenced
with an automated laser fluorescence sequencer (ABI PRISM
3100 Genetic Analyzer, Foster City, WI). Ten-fold serial dilutions
of a known concentration of the product (from 100 pg/mlt o
0.1 pg/ml) were used to establish the standard curve for real-time
PCR. The real-time PCR conditions were as follows: 1 cycle for 20
seconds (sec) at 96uC, followed by 40 cycles of 2 sec at 96uC for
denaturation, 15 sec at 60uC for annealing, and 15 sec at 72uC for
extension. The melting program was performed at 72–95uC with a
heating rate of 1uC per 45 sec. Spectral data were captured and
analyzed using Rotor-Gene Real-Time Analysis Software 6.0
Build 14 (Corbett Research, Mortlake, Australia). All samples were
run in triplicate. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was analyzed as an endogenous RNA reference gene and gene
expression was normalized to the expression of GAPDH.
5. Statistical analysis
To normalize the highly skewed distribution of mRNA
expression levels of C16orf74, the data were natural log
transformed and then back transformed for the interpretation of
the results [34]. Receiver operating characteristics (ROC) curves
were used to determine the optimal cutoff point of the mRNA level
that yielded the highest combined sensitivity and specificity for
progression. Using these values, patients were classified into high
or low C16orf74 expression groups. The Kaplan-Meier method
was used to estimate time to progression, and differences were
assessed using log-rank statistics. The prognostic value of C16orf74
in terms of progression was analyzed using multivariate Cox
proportional hazard regression models. Statistical analysis was
performed using SPSS 12.0 software (SPSS Inc., Chicago, IL), and
a p value of ,0.05 was considered statistically significant.
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